Judith J Prochaska1, Anna Epperson2, Jordan Skan3, Marily Oppezzo2, Paul Barnett4, Kevin Delucchi5, Matthew Schnellbaecher3, Neal L Benowitz6. 1. Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford, CA, USA. Electronic address: jpro@stanford.edu. 2. Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford, CA, USA. 3. Alaska Native Tribal Health Consortium, Cardiology Department, Anchorage, AK, USA. 4. Veterans Affairs Health Economics Resource Center, USA. 5. Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA. 6. Departments of Medicine and Bioengineering & Therapeutic Sciences, Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco, San Francisco, CA, USA.
Abstract
BACKGROUND: Tobacco use and tobacco-related diseases disproportionately affect Alaska Native (AN) people. Using telemedicine, this study aims to identify culturally-tailored, theoretically-driven, efficacious interventions for tobacco use and other cardiovascular disease (CVD) risk behaviors among AN people in remote areas. DESIGN: Randomized clinical trial with two intervention arms: 1) tobacco and physical activity; 2) medication adherence and a heart-healthy AN diet. PARTICIPANTS: Participants are N = 300 AN men and women current smokers with high blood pressure or high cholesterol. INTERVENTIONS: All participants receive motivational, stage-tailored, telemedicine-delivered counseling sessions at baseline and 3, 6, and 12 months follow-up; an individualized behavior change plan that is updated at each contact; and a behavior change manual. In Group 1, the focus is on tobacco and physical activity; a pedometer is provided and nicotine replacement therapy is offered. In Group 2, the focus is on medication adherence for treating hypertension and/or hypercholesterolemia; a medication bag and traditional food guide are provided. MEASUREMENTS: With assessments at baseline, 3, 6, 12, and 18 months, the primary outcome is smoking status, assessed as 7-day point prevalence abstinence, biochemically verified with urine anabasine. Secondary outcomes include physical activity, blood pressure and cholesterol, medication compliance, diet, multiple risk behavior change indices, and cost-effectiveness. COMMENTS: The current study has the potential to identify novel, feasible, acceptable, and efficacious interventions for treating the co-occurrence of CVD risk factors in AN people. Findings may inform personalized treatment and the development of effective and cost-effective intervention strategies for use in remote indigenous communities more broadly. Clinical Trial Registration # NCT02137902.
RCT Entities:
BACKGROUND:Tobacco use and tobacco-related diseases disproportionately affect Alaska Native (AN) people. Using telemedicine, this study aims to identify culturally-tailored, theoretically-driven, efficacious interventions for tobacco use and other cardiovascular disease (CVD) risk behaviors among AN people in remote areas. DESIGN: Randomized clinical trial with two intervention arms: 1) tobacco and physical activity; 2) medication adherence and a heart-healthy AN diet. PARTICIPANTS: Participants are N = 300 AN men and women current smokers with high blood pressure or high cholesterol. INTERVENTIONS: All participants receive motivational, stage-tailored, telemedicine-delivered counseling sessions at baseline and 3, 6, and 12 months follow-up; an individualized behavior change plan that is updated at each contact; and a behavior change manual. In Group 1, the focus is on tobacco and physical activity; a pedometer is provided and nicotine replacement therapy is offered. In Group 2, the focus is on medication adherence for treating hypertension and/or hypercholesterolemia; a medication bag and traditional food guide are provided. MEASUREMENTS: With assessments at baseline, 3, 6, 12, and 18 months, the primary outcome is smoking status, assessed as 7-day point prevalence abstinence, biochemically verified with urine anabasine. Secondary outcomes include physical activity, blood pressure and cholesterol, medication compliance, diet, multiple risk behavior change indices, and cost-effectiveness. COMMENTS: The current study has the potential to identify novel, feasible, acceptable, and efficacious interventions for treating the co-occurrence of CVD risk factors in AN people. Findings may inform personalized treatment and the development of effective and cost-effective intervention strategies for use in remote indigenous communities more broadly. Clinical Trial Registration # NCT02137902.
Authors: David Berrigan; Kevin Dodd; Richard P Troiano; Susan M Krebs-Smith; Rachel Ballard Barbash Journal: Prev Med Date: 2003-05 Impact factor: 4.018
Authors: Lawrence J Fine; G Stephane Philogene; Robert Gramling; Elliot J Coups; Sarbajit Sinha Journal: Am J Prev Med Date: 2004-08 Impact factor: 5.043
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Tony Dans; Alvaro Avezum; Fernando Lanas; Matthew McQueen; Andrzej Budaj; Prem Pais; John Varigos; Liu Lisheng Journal: Lancet Date: 2004 Sep 11-17 Impact factor: 79.321
Authors: Flora Tzelepis; Christine L Paul; Christopher M Williams; Conor Gilligan; Tim Regan; Justine Daly; Rebecca K Hodder; Emma Byrnes; Judith Byaruhanga; Tameka McFadyen; John Wiggers Journal: Cochrane Database Syst Rev Date: 2019-10-29
Authors: Anna E Epperson; Maria Crouch; Jordan Skan; Neal L Benowitz; Matthew Schnellbaecher; Judith J Prochaska Journal: Tob Induc Dis Date: 2020-06-16 Impact factor: 2.600
Authors: Svetlana Semenovna Shadrina; Anna Innokentievna Sivtseva; Elena Nikolaevna Sivtseva; Ara Andreevna Donskaya; Olga Nikolaevna Ivanova Journal: Int J Circumpolar Health Date: 2019-12 Impact factor: 1.228
Authors: Diana G Redwood; Gretchen M Day; Julie A Beans; Vanessa Y Hiratsuka; Sarah H Nash; Barbara V Howard; Jason G Umans; Kathryn R Koller Journal: Curr Dev Nutr Date: 2019-10-09
Authors: Marily Oppezzo; Mariah Knox; Jordan Skan; Amy Chieng; Maria Crouch; Rachael C Aikens; Neal L Benowitz; Matthew Schnellbaecher; Judith J Prochaska Journal: Int J Environ Res Public Health Date: 2022-08-11 Impact factor: 4.614
Authors: Mark A Sanders; Marily Oppezzo; Jordan Skan; Neal L Benowitz; Matthew Schnellbaecher; Judith J Prochaska Journal: PLoS One Date: 2022-09-30 Impact factor: 3.752
Authors: Mariah Knox; Jordan Skan; Neal L Benowitz; Matthew Schnellbaecher; Judith J Prochaska Journal: Int J Circumpolar Health Date: 2020-12 Impact factor: 1.228